Clinical Trials Browser

Neoplasm Metastasis × aldesleukin × Clear all

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase 2 Completed

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT05267626 2026-02-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT00923806 2026-01-23

Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer

Phase 1 Terminated

Neoplasm Metastasis

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1 Terminated

36 enrolled 7 charts

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT02775292 2025-07-30

NYM

Phase 1 Completed

Neoplasm Metastasis

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

Neoplasm Metastasis, Recurrence

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02774291 2023-08-04

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Phase EARLY_PHASE1 Terminated

3 enrolled 6 charts

Brain Neoplasms, Neoplasm Metastasis

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Phase 2 Completed

11 enrolled 12 charts

BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT02390739 2019-12-16

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

Phase 1/2 Withdrawn

Neoplasm Metastasis, Thyroid Neoplasms

NCT01218867 2019-12-10

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Phase 1/2 Terminated

24 enrolled 18 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT01369875 2019-12-10

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Phase 2 Terminated

2 enrolled 8 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00670748 2019-11-19

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2 Terminated

45 enrolled 15 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT01883323 2019-11-08

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Phase 2 Completed

Melanoma, Neoplasm Metastasis

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Phase 1/2 Terminated

15 enrolled 14 charts

GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT02280811 2017-09-06

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Phase 1/2 Completed

12 enrolled 19 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1 Terminated

Melanoma, Neoplasm Metastasis

NCT01754376 2017-04-12

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Phase 2 Terminated

6 enrolled 12 charts

Melanoma, Neoplasm Metastasis

NCT00418496 2017-02-20

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Phase 1 Completed

DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT02062359 2016-06-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Phase 2 Terminated

2 enrolled 7 charts

Melanoma, Neoplasm Metastasis

NCT00924287 2015-10-28

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Phase 1/2 Terminated

1 enrolled 8 charts

Neoplasm Metastasis, Neoplasms

NCT01273181 2015-10-28

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Phase 1/2 Terminated

9 enrolled 13 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00301730 2015-04-28

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00039234 2013-12-18

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Phase 3 Unknown

Melanoma, Neoplasm Metastasis

NCT00588913 2013-07-10

Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases

Phase 1/2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00485563 2012-03-08

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Phase 2 Terminated

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Phase 2 Completed

12 enrolled 10 charts

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms